Aberdeen Group plc grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 157.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 542,866 shares of the pharmaceutical company's stock after purchasing an additional 332,265 shares during the quarter. Aberdeen Group plc owned about 0.21% of Vertex Pharmaceuticals worth $283,816,000 at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in the business. MADDEN SECURITIES Corp purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Meeder Asset Management Inc. acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter worth about $26,000. Community Financial Services Group LLC acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter worth about $26,000. Elevation Wealth Partners LLC grew its stake in Vertex Pharmaceuticals by 103.7% during the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 28 shares during the last quarter. Finally, Pingora Partners LLC purchased a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at about $32,000. 90.96% of the stock is owned by institutional investors and hedge funds.
Vertex Pharmaceuticals Price Performance
Shares of NASDAQ VRTX opened at $538.60 on Friday. The firm has a 50-day simple moving average of $522.37 and a 200-day simple moving average of $483.84. The stock has a market capitalization of $136.56 billion, a price-to-earnings ratio of 31.90, a price-to-earnings-growth ratio of 2.87 and a beta of 0.28. The company has a quick ratio of 1.89, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. Vertex Pharmaceuticals Incorporated has a 52 week low of $412.27 and a 52 week high of $568.67.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The business had revenue of $3.44 billion for the quarter, compared to analysts' expectations of $3.42 billion. During the same period in the prior year, the company posted $4.80 EPS. The firm's revenue was up 11.8% on a year-over-year basis. On average, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on VRTX. Evercore increased their price objective on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an "outperform" rating in a report on Wednesday, September 2nd. Truist Financial boosted their target price on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Cantor Fitzgerald boosted their target price on shares of Vertex Pharmaceuticals from $595.00 to $619.00 and gave the company an "overweight" rating in a research report on Tuesday, November 3rd. Wall Street Zen lowered shares of Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, October 31st. Finally, Scotiabank lifted their price objective on Vertex Pharmaceuticals from $558.00 to $660.00 and gave the company a "sector outperform" rating in a research note on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $596.44.
View Our Latest Stock Analysis on VRTX
Vertex Pharmaceuticals Profile
(
Free Report)
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex's CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
See Also
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.